FEATURED COMPANIES
- Eisai
- GlaxoSmithKline
- GW Pharmaceuticals
- Pfizer
- UCB
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The emergence of biomarkers to gain traction in the market. The world of epilepsy diagnostics is experiencing a trend of emerging biomarkers for epileptogenesis. Epilepsy is the disorder of repeated seizures; hence, these biomarkers for epileptogenesis are used to identify the spontaneity of the seizures. The analysts have predicted that the pediatric epilepsy therapeutics market will register a CAGR of close to 6% by 2023.
Market Overview
Increasing demand for second and third-generation AEDs
The global pediatric epilepsy therapeutics market is witnessing a surge in the number of second-generation AEDs such as felbamate, lamotrigine, as they have low interaction and propensity for cognitive side-effects.
Adverse side effects and increasing social stigma
The global pediatric epilepsy therapeutics market has many approved drugs; however, they are associated with major side effects.
For the detailed list of factors that will drive and challenge the growth of the pediatric epilepsy therapeutics market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Eisai and GlaxoSmithKline the competitive environment is quite intense. Factors such as the emergence of biomarkers and the increasing demand for second and third-generation AEDs, will provide considerable growth opportunities to pediatric epilepsy therapeutics manufactures. Eisai, GlaxoSmithKline, Pfizer, UCB, and GW Pharmaceuticals are some of the major companies covered in this report.
‘With the presence of a considerable number of companies, this market appears to be fragmented. Some of the leading pediatric epilepsy therapeutic companies are forming alliances with organizations and vendors to develop therapeutics that a novel mechanism to make a smoother market entry.’
Market Overview
Increasing demand for second and third-generation AEDs
The global pediatric epilepsy therapeutics market is witnessing a surge in the number of second-generation AEDs such as felbamate, lamotrigine, as they have low interaction and propensity for cognitive side-effects.
Adverse side effects and increasing social stigma
The global pediatric epilepsy therapeutics market has many approved drugs; however, they are associated with major side effects.
For the detailed list of factors that will drive and challenge the growth of the pediatric epilepsy therapeutics market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Eisai and GlaxoSmithKline the competitive environment is quite intense. Factors such as the emergence of biomarkers and the increasing demand for second and third-generation AEDs, will provide considerable growth opportunities to pediatric epilepsy therapeutics manufactures. Eisai, GlaxoSmithKline, Pfizer, UCB, and GW Pharmaceuticals are some of the major companies covered in this report.
‘With the presence of a considerable number of companies, this market appears to be fragmented. Some of the leading pediatric epilepsy therapeutic companies are forming alliances with organizations and vendors to develop therapeutics that a novel mechanism to make a smoother market entry.’
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Eisai
- GlaxoSmithKline
- GW Pharmaceuticals
- Pfizer
- UCB
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 12: VENDOR LANDSCAPE
Exhibit 01: Global epilepsy drugs market
Exhibit 02: Segments of global epilepsy drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Various syndromes of pediatric epilepsy
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Second-generation anti-epileptics - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Second-generation anti-epileptics - Year-over-year growth 2019-2023 (%)
Exhibit 22: Third-generation anti-epileptics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Third-generation anti-epileptics - Year-over-year growth 2019-2023 (%)
Exhibit 24: First-generation anti-epileptics - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: First-generation anti-epileptics approval timeline
Exhibit 26: First-generation anti-epileptics - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Americas
Exhibit 34: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in EMEA
Exhibit 37: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in APAC
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Estimated number of prescriptions for BANZEL (February 1, 2015-May 31, 2017)
Exhibit 43: Overview of late-stage molecules in pipeline
Exhibit 44: Side effects of pediatric epilepsy therapeutics
Exhibit 45: Patent expiration for few noted AEDs
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Eisai - Vendor overview
Exhibit 53: Eisai - Business segments
Exhibit 54: Eisai - Organizational developments
Exhibit 55: Eisai - Segment focus
Exhibit 56: Eisai - Geographic focus
Exhibit 57: Eisai - Key offerings
Exhibit 58: Eisai - Key customers
Exhibit 59: GlaxoSmithKline - Vendor overview
Exhibit 60: GlaxoSmithKline - Business segments
Exhibit 61: GlaxoSmithKline - Organizational developments
Exhibit 62: GlaxoSmithKline - Segment focus
Exhibit 63: GlaxoSmithKline - Geographic focus
Exhibit 64: GlaxoSmithKline - Key offerings
Exhibit 65: GlaxoSmithKline - Key customers
Exhibit 66: GW Pharmaceuticals - Vendor overview
Exhibit 67: GW Pharmaceuticals - Business segments
Exhibit 68: GW Pharmaceuticals - Organizational developments
Exhibit 69: GW Pharmaceuticals - Segment focus
Exhibit 70: GW Pharmaceuticals - Geographic focus
Exhibit 71: GW Pharmaceuticals - Key offerings
Exhibit 72: GW Pharmaceuticals - Key customers
Exhibit 73: Pfizer - Vendor overview
Exhibit 74: Pfizer - Business segments
Exhibit 75: Pfizer - Organizational developments
Exhibit 76: Pfizer - Segment focus
Exhibit 77: Pfizer - Geographic focus
Exhibit 78: Pfizer - Key offerings
Exhibit 79: Pfizer - Key customers
Exhibit 80: UCB - Vendor overview
Exhibit 81: UCB - Business segments
Exhibit 82: UCB - Organizational developments
Exhibit 83: UCB - Geographic focus
Exhibit 84: UCB - Key offerings
Exhibit 85: UCB - Key customers
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by product
- Comparison by product
- Second-generation anti-epileptics - Market size and forecast 2018-2023
- Third-generation anti-epileptics - Market size and forecast 2018-2023
- First-generation anti-epileptics - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Eisai
- GlaxoSmithKline
- GW Pharmaceuticals
- Pfizer
- UCB
- Research methodology
- List of abbreviations
Exhibit 01: Global epilepsy drugs market
Exhibit 02: Segments of global epilepsy drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Various syndromes of pediatric epilepsy
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Second-generation anti-epileptics - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Second-generation anti-epileptics - Year-over-year growth 2019-2023 (%)
Exhibit 22: Third-generation anti-epileptics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Third-generation anti-epileptics - Year-over-year growth 2019-2023 (%)
Exhibit 24: First-generation anti-epileptics - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: First-generation anti-epileptics approval timeline
Exhibit 26: First-generation anti-epileptics - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Americas
Exhibit 34: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in EMEA
Exhibit 37: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in APAC
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Estimated number of prescriptions for BANZEL (February 1, 2015-May 31, 2017)
Exhibit 43: Overview of late-stage molecules in pipeline
Exhibit 44: Side effects of pediatric epilepsy therapeutics
Exhibit 45: Patent expiration for few noted AEDs
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Eisai - Vendor overview
Exhibit 53: Eisai - Business segments
Exhibit 54: Eisai - Organizational developments
Exhibit 55: Eisai - Segment focus
Exhibit 56: Eisai - Geographic focus
Exhibit 57: Eisai - Key offerings
Exhibit 58: Eisai - Key customers
Exhibit 59: GlaxoSmithKline - Vendor overview
Exhibit 60: GlaxoSmithKline - Business segments
Exhibit 61: GlaxoSmithKline - Organizational developments
Exhibit 62: GlaxoSmithKline - Segment focus
Exhibit 63: GlaxoSmithKline - Geographic focus
Exhibit 64: GlaxoSmithKline - Key offerings
Exhibit 65: GlaxoSmithKline - Key customers
Exhibit 66: GW Pharmaceuticals - Vendor overview
Exhibit 67: GW Pharmaceuticals - Business segments
Exhibit 68: GW Pharmaceuticals - Organizational developments
Exhibit 69: GW Pharmaceuticals - Segment focus
Exhibit 70: GW Pharmaceuticals - Geographic focus
Exhibit 71: GW Pharmaceuticals - Key offerings
Exhibit 72: GW Pharmaceuticals - Key customers
Exhibit 73: Pfizer - Vendor overview
Exhibit 74: Pfizer - Business segments
Exhibit 75: Pfizer - Organizational developments
Exhibit 76: Pfizer - Segment focus
Exhibit 77: Pfizer - Geographic focus
Exhibit 78: Pfizer - Key offerings
Exhibit 79: Pfizer - Key customers
Exhibit 80: UCB - Vendor overview
Exhibit 81: UCB - Business segments
Exhibit 82: UCB - Organizational developments
Exhibit 83: UCB - Geographic focus
Exhibit 84: UCB - Key offerings
Exhibit 85: UCB - Key customers
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Eisai
- GlaxoSmithKline
- GW Pharmaceuticals
- Pfizer
- UCB
Global Pediatric Epilepsy Therapeutics Market 2018-2022
The author of the report recognizes the following companies as the key players in the global pediatric epilepsy therapeutics market: Eisai, GlaxoSmithKline, Pfizer, UCB, and GW Pharmaceuticals.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the emergence of biomarkers.”
According to the report, one of the major drivers for this market is the increasing demand for second and third-generation AEDs.
Further, the report states that one of the major factors hindering the growth of this market is the adverse side effects and increasing social stigma.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The author of the report recognizes the following companies as the key players in the global pediatric epilepsy therapeutics market: Eisai, GlaxoSmithKline, Pfizer, UCB, and GW Pharmaceuticals.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the emergence of biomarkers.”
According to the report, one of the major drivers for this market is the increasing demand for second and third-generation AEDs.
Further, the report states that one of the major factors hindering the growth of this market is the adverse side effects and increasing social stigma.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- Eisai
- GlaxoSmithKline
- GW Pharmaceuticals
- Pfizer
- UCB
Note: Product cover images may vary from those shown
LOADING...
